IP Library Granted Patent US 7,462,360
Granted Patent B2
US 7,462,360 · App. 10/742,864 · Granted Dec 9, 2008

Alloferons—immunomodulatory peptides

Assignee: Entopharm Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,462,360
App. No.
10/742,864
Granted
Dec 9, 2008
Kind
B2
Abstract

The invention belongs to the field of biologically active peptides specifically stimulating antiviral, antimicrobial and antitumor activity of the human and animal immune system.

Claims (7)

1. A method of manufacturing a composition having immunomodulatory activity, comprising combining a peptide of up to 30 amino acid residues comprising the amino acid sequence of any one of SEQ ID NOS: 1-4, or a pharmaceutically active salt or ether of the peptide with a conventional additive.

2. The method of claim 1 , wherein said peptide comprises SEQ ID NO:4.

3. The method of claim 1 , wherein the peptide consists of less than 30 amino acids.

4. The method of claim 1 , wherein the composition is a pharmaceutical that exhibits at least one of interferon inducing activity, antiviral activity, antitumor activity or stimulation of the cytotoxic activity of human or animal lymphocytes.

5. The method of claim 1 , wherein the composition is a pharmaceutical useful for the treatment or prophylaxis of at least one of an immune deficient condition, an infection, a viral infection, a fungal systemic infection, and an oncological disease.

6. A method of treating a condition, comprising administering to a subject in need thereof an effective amount of the immunomodulatory composition made by the method of claim 1 .

7. The method of claim 6 wherein said condition is selected from the group consisting of an immune deficient condition, an infection and an oncology.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 23, 2021
From: ALLOFERON, INC.
To: HBSCIENCE CO., LTD.; ALLOFERON, INC.
Reel/Frame 055365/0808 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2016
From: AT-PHARMA EUROPE GMBH
To: ALLOFERON, INC.
Reel/Frame 040242/0172 →
MERGER Recorded Jun 23, 2016
From: OOST-MARKT PHARMACEUTICAL CONSULTING B.V.
To: AT-PHARMA EUROPE GMBH
Reel/Frame 038996/0992 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2010
From: ENTOPHARM CO., LTD.
To: LEHIGH VALLEY TECHNOLOGIES, INC.
Reel/Frame 023814/0575 →
Priority Claims (1)
RU 99127725 · Dec 27, 1999 · national
Continuity (2)
Division 0974811400 · Dec 27, 2000
Related Publication 20040138137A1 · Jul 15, 2004